New Katagiri Score (Skeletal Metastasis Survival)
The new Katagiri score (Katagiri and colleagues 2014) estimates survival in a patient with symptomatic skeletal metastasis, six factors totalling 0 to 10.
Open the calculator → Runs in your browser. Data leaves only if you deliberately send a problem report from the interactive tool.
Example
- Primary site GROWTH-RATE group, NOT the organ
- Rapid growth
- Visceral or cerebral metastases
- Nodular visceral or cerebral metastasis
- C-reactive protein at or above 0.4 mg/dL
- No
- Lactate dehydrogenase at or above 250 IU/L
- No
- Serum albumin below 3.7 g/dL
- No
- Platelets below 100,000 per microliter
- No
- Serum calcium at or above 10.3 mg/dL
- No
- Total bilirubin at or above 1.4
- No
- ECOG performance status 3 or 4
- No
- Previous chemotherapy
- No
- Multiple skeletal metastases
- No
Result: 4
The tool opens with these values already filled in. Replace them with your own.
What the result means
- Primary site
- BY TREATABILITY, NOT ORGAN: slow 0, moderate 2, rapid 3. Breast/prostate are SLOW if hormone-dependent, MODERATE if not; lung MODERATE if targeted, RAPID if not.
- Visceral
- None 0; nodular 1; disseminated (pleural, peritoneal, leptomeningeal) 2.
- Labs abnormal
- 1 point: CRP at or above 0.4 mg/dL, LDH at or above 250 IU/L, or albumin below 3.7 g/dL.
- Labs critical
- 2 points: platelets below 100,000/uL, calcium at or above 10.3 mg/dL, or bilirubin at or above 1.4. A DIFFERENT ANALYTE SET.
- Tiers
- THE TIERS SHARE NO ANALYTE. All three abnormal values score 1; one critical value scores 2. Any-of within a tier; never 3.
- One-pointers
- ECOG 3-4; previous chemotherapy; multiple skeletal metastases.
- 0 to 3
- Low risk. 91% one-year survival in the derivation cohort.
- 4 to 6
- Intermediate risk. 49%.
- 7 to 10
- High risk. 6%.
- Provenance
- The 2014 score ADDED the laboratory item to a 2005 predecessor. Derived in a mostly NON-SURGICAL cohort.
- Scope
- Group-level survival. Does not decide whether to operate, choose a modality, or grade the bone.
What you enter
- Primary site GROWTH-RATE group, NOT the organ
- Visceral or cerebral metastases
- C-reactive protein at or above 0.4 mg/dL.
- Lactate dehydrogenase at or above 250 IU/L.
- Serum albumin below 3.7 g/dL.
- Platelets below 100,000 per microliter.
- Serum calcium at or above 10.3 mg/dL.
- Total bilirubin at or above 1.4.
- ECOG performance status 3 or 4.
- Previous chemotherapy.
- Multiple skeletal metastases.
Full field descriptions
- Primary site GROWTH-RATE group, NOT the organ [slow = 0, covering hormone-DEPENDENT breast or prostate cancer, thyroid cancer, multiple myeloma, malignant lymphoma; moderate = 2, covering molecularly targeted lung cancer, hormone-INDEPENDENT breast or prostate cancer, renal cell carcinoma, sarcoma; rapid = 3, covering non-targeted lung cancer, colorectal, gastric, pancreatic, head and neck, esophageal, hepatocellular carcinoma, melanoma, and cancer of unknown origin]
- Visceral or cerebral metastases [none = 0; nodular = 1; disseminated = 2]
- C-reactive protein at or above 0.4 mg/dL. ABNORMAL tier - any one gives 1 point. This tier shares no analyte with the critical tier.
- Lactate dehydrogenase at or above 250 IU/L. ABNORMAL tier - any one gives 1 point. This tier shares no analyte with the critical tier.
- Serum albumin below 3.7 g/dL. ABNORMAL tier - any one gives 1 point. This tier shares no analyte with the critical tier.
- Platelets below 100,000 per microliter. CRITICAL tier - any one gives 2 points and OUTRANKS the abnormal tier. A different analyte set entirely.
- Serum calcium at or above 10.3 mg/dL. CRITICAL tier - any one gives 2 points and OUTRANKS the abnormal tier. A different analyte set entirely.
- Total bilirubin at or above 1.4. CRITICAL tier - any one gives 2 points and OUTRANKS the abnormal tier. A different analyte set entirely.
- ECOG performance status 3 or 4. 1 point.
- Previous chemotherapy. 1 point.
- Multiple skeletal metastases. 1 point.
How this is calculated
Katagiri H, Okada R, Takagi T, et al. New prognostic factors and scoring system for patients with skeletal metastasis. Cancer Med. 2014;3(5):1359-1367. Read the source ↗
A reference and educational tool. Not medical, legal, or financial advice, and not a substitute for clinician judgment.